Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for LINE and 80,000+ other tickers.
See exactly how LINE's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LINE and 80,000+ other tickers.
Lineage, Inc. is the world’s largest global temperature-controlled warehouse REIT with a network of 498 strategically located facilities totaling approximately 87 million square feet and approximately 3.1 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific, as of June 30, 2026. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Lineage, Inc. was established in 2015 and was incorporated in Maryland.
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ® THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ – VALU ) announced today that its Board of Directors declared on October 16, 2026 a quarterly cash dividend of $0.35 per common share, payable on November 10, 2026, to stockholders of record on October 26, 2026. The Company has 9,382,098 shares of common stock outstanding as of October 16, 2026.
NOVI, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lineage, Inc. (NASDAQ: LINE), announced that it will report its financial results for the third quarter of 2026 on Monday, November 9, 2026, after market close. A conference call to discuss these results has been scheduled for 8:00 a.m. Eastern Time on Tuesday, November 10, 2026.
JACKSONVILLE, Fla. and NOVI, Mich.
Lineage, Inc. (NASDAQ: LINE - Get Free Report) declared a quarterly dividend on Tuesday, September 15th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.5325 per share on Wednesday, October 21st. This represents a $2.13 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date is Wednesday, September